Literature DB >> 12747950

Immunosuppressive effects of a Kv1.3 inhibitor.

Kashmira Shah1, J Tom Blake, Christopher Huang, Paul Fischer, Gloria C Koo.   

Abstract

The voltage gated potassium channel (Kv1.3) has been shown to play a role in immune responsiveness. Blockade of the channel led to diminution of T cell activation and delayed type hypersensitivity. Previous in vitro studies of the blockade were focused on T cell activation and proliferation. In this study we examined other T and monocytic cell mediated events to glean the extent of the immunosuppressive effects of a Kv1.3 specific inhibitor, Margatoxin (MgTX). We found that MgTX inhibited the intracellular production of Th-1 as well as Th-2 cytokines. MgTX can also inhibit IL-2 production and proliferation of T cells upon stimulation with anti-CD3 and VCAM-1. Furthermore, a redirected cytolytic activity was also inhibited by MgTX. However, MgTX did not inhibit generation of CTL to EBV transformed lymphoma cells or antibody-dependent cellular cytolysis mediated by monocytes. It appears that a Kv1.3 blockade does not affect all immune responses, particularly those of innate immunity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12747950     DOI: 10.1016/s0008-8749(03)00063-7

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  8 in total

1.  Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques.

Authors:  L E Pereira; F Villinger; H Wulff; A Sankaranarayanan; G Raman; A A Ansari
Journal:  Exp Biol Med (Maywood)       Date:  2007-11

2.  Crystallization and preliminary X-ray diffraction studies of the tetramerization domain derived from the human potassium channel Kv1.3.

Authors:  Andreas Winklmeier; Michael Weyand; Christina Schreier; Hans Robert Kalbitzer; Werner Kremer
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-06-27

3.  Recombinant Kv channels at the membrane of Escherichia coli bind specifically agitoxin2.

Authors:  Oksana V Nekrasova; Anastasia A Ignatova; Anna I Nazarova; Alexey V Feofanov; Yuliya V Korolkova; Elena F Boldyreva; Anna I Tagvei; Eugene V Grishin; Alexander S Arseniev; Mikhail P Kirpichnikov
Journal:  J Neuroimmune Pharmacol       Date:  2008-07-23       Impact factor: 4.147

4.  Kv1.3 channel blocker (ImKTx88) maintains blood-brain barrier in experimental autoimmune encephalomyelitis.

Authors:  Jie Huang; Song Han; Qi Sun; Yipeng Zhao; Junchen Liu; Xiaolu Yuan; Wenqian Mao; Biwen Peng; Wanhong Liu; Jun Yin; Xiaohua He
Journal:  Cell Biosci       Date:  2017-06-07       Impact factor: 7.133

5.  Cyclotides Suppress Human T-Lymphocyte Proliferation by an Interleukin 2-Dependent Mechanism.

Authors:  Carsten Gründemann; Kathrin Thell; Karin Lengen; Manuel Garcia-Käufer; Yen-Hua Huang; Roman Huber; David J Craik; Gernot Schabbauer; Christian W Gruber
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

6.  Recombinant expression of margatoxin and agitoxin-2 in Pichia pastoris: an efficient method for production of KV1.3 channel blockers.

Authors:  Raveendra Anangi; Shyny Koshy; Redwan Huq; Christine Beeton; Woei-Jer Chuang; Glenn F King
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

Review 7.  The voltage-dependent K(+) channels Kv1.3 and Kv1.5 in human cancer.

Authors:  Núria Comes; Joanna Bielanska; Albert Vallejo-Gracia; Antonio Serrano-Albarrás; Laura Marruecos; Diana Gómez; Concepció Soler; Enric Condom; Santiago Ramón Y Cajal; Javier Hernández-Losa; Joan C Ferreres; Antonio Felipe
Journal:  Front Physiol       Date:  2013-10-10       Impact factor: 4.566

Review 8.  Dendritic Cell Regulation by Cannabinoid-Based Drugs.

Authors:  Mattias Svensson; Puran Chen; Oscar Hammarfjord
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.